No abstract available
Publication types
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antithrombin III / analysis
-
Aspirin / administration & dosage
-
Aspirin / adverse effects
-
Aspirin / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Fibrin Fibrinogen Degradation Products / analysis
-
Hemorrhage / chemically induced
-
Hemorrhage / epidemiology
-
Humans
-
Hydroxyurea / adverse effects
-
Hydroxyurea / therapeutic use
-
Male
-
Middle Aged
-
Peptide Fragments / analysis
-
Peptide Hydrolases / analysis
-
Platelet Activation / drug effects*
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / pharmacology
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Count
-
Platelet Factor 4 / analysis
-
Prothrombin / analysis
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects
-
Quinazolines / pharmacology*
-
Quinazolines / therapeutic use
-
Thrombocythemia, Essential / blood
-
Thrombocythemia, Essential / drug therapy*
-
Thrombosis / epidemiology
-
Thrombosis / etiology
Substances
-
Fibrin Fibrinogen Degradation Products
-
Peptide Fragments
-
Platelet Aggregation Inhibitors
-
Quinazolines
-
antithrombin III-protease complex
-
fibrin fragment D
-
prothrombin fragment 1.2
-
Platelet Factor 4
-
Antithrombin III
-
Prothrombin
-
Peptide Hydrolases
-
anagrelide
-
Aspirin
-
Hydroxyurea